Results 251 to 260 of about 446,168 (357)

Pharmacokinetics, Safety, and Skin Irritation and Sensitization Potential of Clascoterone Cream in Early‐Phase Clinical Study Participants

Clinical Pharmacology in Drug Development, EarlyView.
Abstract Clascoterone is an androgen receptor inhibitor approved for the treatment of acne vulgaris in patients 12 years of age and older. Here, we report results of 5 phase 1 studies that assessed the pharmacokinetics (PK), safety, and skin irritation and sensitization potential of clascoterone cream 1% in healthy participants and patients with acne ...
Andrea Francesco Daniele Di Stefano, Milko Massimiliano Radicioni, Gerhard Garhöfer, Martina Cartwright, Markus Müller, Iris Kopeloff, Luigi Moro, Nicholas Squittieri, Alessandro Mazzetti   +8 more
wiley   +1 more source

A phase Ib/II trial of atezolizumab with cobimetinib or idasanutlin in metastatic estrogen receptor positive breast cancer. [PDF]

NPJ Breast Cancer
Mezzanotte-Sharpe J, Taylor BC, Gonzalez-Ericsson PI, Sanchez V, Ocampo AA, Marshall JL, Steele JA, Sanders ME, Mayer IA, Balko JM, Kennedy LC.   +10 more
europepmc   +1 more source

A Study of Cytoplasmic and Nuclear Estrogen and Progestin Receptors in Gynecologic Neoplasms

, 1987
H Sakamoto, Neil J. MacLusky, Peter E. Schwartz, Frederick Naftolin, D Phil, K Den, Shigeo Takagi   +6 more
openalex   +2 more sources

Disposition and Absolute Bioavailability of Oral Imlunestrant in Healthy Women: A Phase 1, Open‐Label Study

Clinical Pharmacology in Drug Development, EarlyView.
Abstract Imlunestrant (LY3484356) is a next‐generation orally bioavailable selective estrogen receptor degrader being investigated for the treatment of estrogen receptor–positive advanced breast and endometrial cancers. This Phase 1, open‐label, 2‐part study evaluated the disposition and absolute bioavailability of [14C]‐imlunestrant in 16 US‐based ...
Amita Datta‐Mannan, Boris Czeskis, Elaine Shanks, Eunice Yuen, Stephen Hall, Vivian Rodriguez Cruz, Kenneth Cassidy   +6 more
wiley   +1 more source

Predicting estrogen receptor status from HE-stained breast cancer slides using artificial intelligence. [PDF]

Front Med (Lausanne)
Høibø M, Spiske U, Pedersen A, Ytterhus B, Akslen LA, Wik E, Askeland C, Reinertsen I, Smistad E, Valla M.   +9 more
europepmc   +1 more source

Experimental studies on hepatocarcinogenesis induced by oral contraceptives, with special reference to estrogen receptor and the effect of tamoxifen.

, 1987
Masasumi OHTA
openalex   +2 more sources

Supplementing Single‐Arm Trials with External Control Arms—Evaluation of German Real‐World Data

Clinical Pharmacology &Therapeutics, EarlyView.
As single‐arm trials (SATs) are increasingly used in pharmaceutical research, the validity of such study designs needs to be critically assessed. We characterize the feasibility of supplementing SATs with real‐world data (RWD)‐derived external control arms by determining the proportion of SATs on breast cancer and amyotrophic lateral sclerosis (ALS ...
Martin Russek, Jonas Peltner, Britta Haenisch   +2 more
wiley   +1 more source

Imlunestrant a next-generation oral SERD overcomes ESR1 mutant resistance in estrogen receptor-positive breast cancer. [PDF]

JCI Insight
Sherman S, Sandusky ZM, Russo D, Zak D, Nardone A, Friel D, Hermida-Prado F, Heraud C, Kuziel G, Verma A, Gaglia G, Kabraji S, Nguyen QD, Santagata S, Fanning SW, Jeselsohn R.   +15 more
europepmc   +1 more source

Studies on the Estrogen Receptor in Human Meningioma and Thymoma

, 1982
Shunzo Kobayashi, Norihiko Tobioka, Tsuneo Samoto, Hironori Tanaka, Akira Masaoka   +4 more
openalex   +2 more sources

Repurposing Acebutolol for Osteoporosis Treatment: Insights From Multi‐Omics and Multi‐Modal Data Analysis

Clinical Pharmacology &Therapeutics, EarlyView.
Overview of a multi‐omics based drug repurposing strategy. The systematic drug repurposing strategy included the following steps: (1) osteoporosis driver signaling networks were identified from multi‐omics data; (2) drug functional modules were obtained using a network fusion approach to integrate drug similarity information; (3) all drugs were ranked ...
Dan‐Yang Liu, Hui Shen, Jonathan Greenbaum, Qiao‐Rong Yi, Shuang Liang, Yue Zhang, Jia‐Chen Liu, Chuan Qiu, Lan‐Juan Zhao, Qing Tian, Kuan‐Jui Su, Zhe Luo, Li Wu, Xiang‐He Meng, Hong‐Mei Xiao, Yun Deng, Yang Li, Dragana Lovre, Vivian Fonseca, Fernando L. Sanchez, Li‐Jun Tan, Hong‐Wen Deng   +21 more
wiley   +1 more source